Please assess the completion status of the following clinical trial:

Trial Title: A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants diagnosed with symptomatic or nonsecretory multiple myeloma~* Participants who have not received chemotherapy and are not hematopoietic stem cell transplantation candidates~* Participants with a measurable lesion~* Life expectancy greater than or equal to 3 months~Exclusion Criteria:~* Previously received treatment for Multiple Myeloma~* Greater than or equal to Grade 2 peripheral neuropathy or neuropathic pain~* Myocardial infarction within 6 months prior to enrollment or uncontrolled angina, severe uncontrolled ventricular arrhythmias, or clinically significant conduction system abnormalities~* Patient is known to be seropositive for the human immunodeficiency virus (HIV), Hepatitis B surface antigen-positive or active hepatitis C infection~* Active prior malignancy diagnosed within the last 5 years~* Female participant who is pregnant or breast-feeding~* Participant is enrolled in another clinical research study and/or is receiving an investigational agent

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I: JNJ-26866138 0.7 mg/m2 (Type: EXPERIMENTAL): JNJ-26866138 0.7 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles.
- Phase I: JNJ-26866138 1.0 mg/m2 (Type: EXPERIMENTAL): JNJ-26866138 1.0 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
- Phase I: JNJ-26866138 1.3 mg/m2 (Type: EXPERIMENTAL): JNJ-26866138 1.3 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
- Phase II: JNJ-26866138 1.3 mg/m2 (Type: EXPERIMENTAL): JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5-9 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).